In PCa patients, a high neutrophil-to-lymphocyte ratio (NLR) is associated with shorter OS (11), biochemical recurrence after RP, high PSA and Gleason score (12–14), compared to patients with low NLR, being considered as a valid prognostic biomarker for CRPC patients treated with second-line chemotherapy (15). The gene discussed is KLK3; the disease is posterior cortical atrophy.